Consortium consisting of Nordic Capital and Permira increases offer price for Bavarian Nordic to DKK 250 per share from DKK 233; extends offer period to 5-Nov (DKK 230.50, 0.00)
Bavarian Nordic obtains all regulatory approvals required to satisfy the regulatory conditions under Permira's offer (DKK 230.90, -0.70)
EU clears Consortium's acquisition of Bavarian Nordic A/S (DKK 229.30, -2.30)
Bavarian Nordic reports topline results from a clinical study of its MVA-BN mpox/smallpox vaccine in children 2 to 11 years of age; Primary endpoint was met (DKK 229.80, 0.00)
Consortium consisting of Nordic Capital and Permira extends offer period until 14-Oct-25 and provides update on regulatory approvals in respect of the takeover offer to the shareholders of Bavarian Nordic (DKK 228.50, +0.50)
StreetAccount M&A Summary: Week of 25-Aug
Follow-up: Consortium lowers the minimum acceptance condition in connection with offer for Bavarian Nordic from more than 90% to 75% of the shares (DKK 237.80, 0.00)
Bavarian Nordic's board unanimously recommends shareholders accept consortium's DKK233/share in cash offer (DKK 237.80, 0.00)
StreetAccount Sector Summary - Healthcare Post-Market
StreetAccount Sector Summary - Healthcare Pre-Market
Powered by FactSet Research Systems Inc.